GILD vs. SNN: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at GILD and SNN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
GILD is a standard domestic listing, while SNN trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | GILD | SNN |
|---|---|---|
| Company Name | Gilead Sciences, Inc. | Smith & Nephew plc |
| Country | United States | United Kingdom |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Equipment & Supplies |
| Market Capitalization | 155.60 billion USD | 13.96 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | January 22, 1992 | November 16, 1999 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of GILD and SNN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | GILD | SNN |
|---|---|---|
| 5-Day Price Return | 5.81% | -1.70% |
| 13-Week Price Return | 5.62% | -7.64% |
| 26-Week Price Return | 23.26% | 15.12% |
| 52-Week Price Return | 34.97% | 26.96% |
| Month-to-Date Return | 4.37% | -11.39% |
| Year-to-Date Return | 35.35% | 25.58% |
| 10-Day Avg. Volume | 7.40M | 2.06M |
| 3-Month Avg. Volume | 6.78M | 2.34M |
| 3-Month Volatility | 22.76% | 27.04% |
| Beta | 0.34 | 1.05 |
Profitability
Return on Equity (TTM)
GILD
40.74%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
In the upper quartile for the Biotechnology industry, GILD’s Return on Equity of 40.74% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
SNN
9.09%
Health Care Equipment & Supplies Industry
- Max
- 29.82%
- Q3
- 15.54%
- Median
- 9.69%
- Q1
- 5.19%
- Min
- -7.98%
SNN’s Return on Equity of 9.09% is on par with the norm for the Health Care Equipment & Supplies industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
GILD
27.88%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
A Net Profit Margin of 27.88% places GILD in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
SNN
8.26%
Health Care Equipment & Supplies Industry
- Max
- 24.65%
- Q3
- 14.10%
- Median
- 10.09%
- Q1
- 5.84%
- Min
- -6.13%
SNN’s Net Profit Margin of 8.26% is aligned with the median group of its peers in the Health Care Equipment & Supplies industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
GILD
36.06%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
An Operating Profit Margin of 36.06% places GILD in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
SNN
12.75%
Health Care Equipment & Supplies Industry
- Max
- 31.34%
- Q3
- 18.36%
- Median
- 15.07%
- Q1
- 9.62%
- Min
- -0.13%
SNN’s Operating Profit Margin of 12.75% is around the midpoint for the Health Care Equipment & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | GILD | SNN |
|---|---|---|
| Return on Equity (TTM) | 40.74% | 9.09% |
| Return on Assets (TTM) | 14.12% | 4.67% |
| Net Profit Margin (TTM) | 27.88% | 8.26% |
| Operating Profit Margin (TTM) | 36.06% | 12.75% |
| Gross Profit Margin (TTM) | 78.72% | 70.04% |
Financial Strength
Current Ratio (MRQ)
GILD
1.53
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
GILD’s Current Ratio of 1.53 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
SNN
3.00
Health Care Equipment & Supplies Industry
- Max
- 4.97
- Q3
- 2.92
- Median
- 2.12
- Q1
- 1.54
- Min
- 0.86
SNN’s Current Ratio of 3.00 is in the upper quartile for the Health Care Equipment & Supplies industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
Debt-to-Equity Ratio (MRQ)
GILD
1.27
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
GILD’s leverage is in the upper quartile of the Biotechnology industry, with a Debt-to-Equity Ratio of 1.27. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
SNN
0.62
Health Care Equipment & Supplies Industry
- Max
- 1.62
- Q3
- 0.74
- Median
- 0.47
- Q1
- 0.15
- Min
- 0.00
SNN’s Debt-to-Equity Ratio of 0.62 is typical for the Health Care Equipment & Supplies industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
GILD
1.71
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
GILD’s Interest Coverage Ratio of 1.71 is positioned comfortably within the norm for the Biotechnology industry, indicating a standard and healthy capacity to cover its interest payments.
SNN
4.80
Health Care Equipment & Supplies Industry
- Max
- 56.35
- Q3
- 24.86
- Median
- 9.84
- Q1
- 3.86
- Min
- -21.65
SNN’s Interest Coverage Ratio of 4.80 is positioned comfortably within the norm for the Health Care Equipment & Supplies industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | GILD | SNN |
|---|---|---|
| Current Ratio (MRQ) | 1.53 | 3.00 |
| Quick Ratio (MRQ) | 1.17 | 1.40 |
| Debt-to-Equity Ratio (MRQ) | 1.27 | 0.62 |
| Interest Coverage Ratio (TTM) | 1.71 | 4.80 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
GILD
2.54%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
GILD’s Dividend Yield of 2.54% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.
SNN
2.35%
Health Care Equipment & Supplies Industry
- Max
- 4.36%
- Q3
- 1.87%
- Median
- 0.82%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 2.35%, SNN offers a more attractive income stream than most of its peers in the Health Care Equipment & Supplies industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
GILD
62.75%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
At 62.75%, GILD’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
SNN
66.60%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 67.77%
- Median
- 28.21%
- Q1
- 0.00%
- Min
- 0.00%
SNN’s Dividend Payout Ratio of 66.60% is within the typical range for the Health Care Equipment & Supplies industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | GILD | SNN |
|---|---|---|
| Dividend Yield (TTM) | 2.54% | 2.35% |
| Dividend Payout Ratio (TTM) | 62.75% | 66.60% |
Valuation
Price-to-Earnings Ratio (TTM)
GILD
19.23
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
GILD’s P/E Ratio of 19.23 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
SNN
28.38
Health Care Equipment & Supplies Industry
- Max
- 67.59
- Q3
- 41.41
- Median
- 33.11
- Q1
- 22.82
- Min
- 8.68
SNN’s P/E Ratio of 28.38 is within the middle range for the Health Care Equipment & Supplies industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
GILD
5.36
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
GILD’s P/S Ratio of 5.36 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
SNN
2.34
Health Care Equipment & Supplies Industry
- Max
- 9.49
- Q3
- 5.41
- Median
- 2.92
- Q1
- 1.97
- Min
- 0.61
SNN’s P/S Ratio of 2.34 aligns with the market consensus for the Health Care Equipment & Supplies industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
GILD
6.42
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
GILD’s P/B Ratio of 6.42 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
SNN
2.32
Health Care Equipment & Supplies Industry
- Max
- 10.77
- Q3
- 6.04
- Median
- 3.32
- Q1
- 2.31
- Min
- 0.83
SNN’s P/B Ratio of 2.32 is within the conventional range for the Health Care Equipment & Supplies industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | GILD | SNN |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 19.23 | 28.38 |
| Price-to-Sales Ratio (TTM) | 5.36 | 2.34 |
| Price-to-Book Ratio (MRQ) | 6.42 | 2.32 |
| Price-to-Free Cash Flow Ratio (TTM) | 16.76 | 17.48 |